After $1Bn manufacturing issues, Weldon to make way as J&J picks insider Gorsky for CEO
This article was originally published in Scrip
Executive Summary
Johnson & Johnson has announced that its CEO of the past 10 years, Bill Weldon, is to stand down in April, making way for Alex Gorsky, current head of the group's medical devices and diagnostics division. It is not clear if Mr Weldon's departure was forced by the string of manufacturing quality issues and product recalls that have knocked $1 billion off J&J's sales, but succession planning had been going on for some time. Mr Weldon will stay on in his existing role as chairman of the board of directors.Mr Gorsky was one of two internal candidates being groomed as potential successors to Mr Weldon. He and Sheri McCoy, who runs the pharmaceuticals and consumer product groups of the US healthcare giant, were both named vice-chairs of the executive committee back in January 2011 as part of the process, which also looked at outside candidates. Mr Weldon described the decision as the conclusion of a "rigorous, thorough and formal multi-year process".
You may also be interested in...
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.